AOD-9604 Dosage and Cycling: Injection Timing, Fasted Cardio Stack, and Maintenance (2026)

AOD-9604 Dosage: What the Clinical Data Actually Says

AOD-9604 dosage in clinical research ranged from 250 mcg to 10 mg daily, with the 1 mg/day arm producing the best documented weight loss result: 2.6 kg over 12 weeks versus 0.8 kg placebo. For subcutaneous research use, 250–500 mcg daily is the working range most practitioners cite, based on six clinical trials involving approximately 900 participants.

AOD-9604 (also catalogued as hGH Fragment 176–191 or Tyr-hGH 177–191) is a 16-amino-acid synthetic peptide derived from the C-terminal region of human growth hormone. The core premise is metabolic selectivity: it activates the lipolytic machinery of fat tissue without engaging the growth hormone receptor or elevating IGF-1. That separation is clinically documented and is the reason researchers continue to study this molecule despite the commercial development programme ending in 2007.

This guide covers the mechanics of AOD-9604 dosage, injection timing, fasted cardio stacking logic, and cycling structure. All protocol-level guidance is based on published data and preclinical evidence cited inline. Where evidence is anecdotal or practitioner-derived, it is labelled as such.

Affiliate disclosure: This post contains links to a recommended research compound supplier. We earn a commission if you purchase via those links. This does not influence the clinical analysis. See our recommended sources page for vendor-neutral sourcing guidance.

The Mechanism Behind AOD-9604 Dosage Decisions

AOD-9604 stimulates lipolysis and inhibits lipogenesis through beta-3 adrenergic receptor activation in adipose tissue, operating independently of the growth hormone receptor and IGF-1 axis. That receptor-level mechanism is why dosage does not follow a simple linear dose-response curve and why higher doses do not produce proportionally greater fat loss.

Understanding the pharmacology shapes the dosage logic. Unlike full-length human growth hormone, which binds the GH receptor and elevates IGF-1, AOD-9604 acts through a diacylglycerol second-messenger pathway in fat cells. The original patent documentation describes this mechanism in detail, noting that the peptide stimulates lipolysis and inhibits lipogenesis via beta-adrenergic signalling at concentrations far below those needed to activate growth-promoting pathways. Ng 2002

Preclinical data in obese Zucker rats confirmed that 500 mcg/kg/day by intraperitoneal injection for 18 days preserved insulin sensitivity, unlike intact hGH. Heffernan 2001a Mouse studies using chronic osmotic pump delivery showed AOD-9604 increased fat oxidation and plasma glycerol (a lipolysis marker) to a degree comparable with full-length hGH, without inducing hyperglycaemia or reducing insulin secretion. Heffernan 2001b

This metabolic selectivity has a dosage implication: once the beta-3 receptors in adipose tissue are adequately occupied, additional peptide does not proportionally increase the lipolytic signal. Clinical trial data confirmed this directly.

Clinical Trial Dosage Findings: What the Human Data Shows

The Phase II clinical trials tested doses from 1 mg/day up to 10 mg/day. The 1 mg/day arm produced 2.6 kg weight loss over 12 weeks versus 0.8 kg placebo. The 10 mg/day arm showed a smaller reduction than the 1 mg group, confirming the absence of a dose-dependent response above the threshold range.

In the 12-week randomised controlled trial documented in the obesity pharmacotherapy literature, the 1 mg/day group achieved statistically meaningful separation from placebo. The 10 mg/day arm produced a smaller result than the 1 mg arm, not a larger one. Cooke 2011 This non-linear dose-response is characteristic of peptides that operate through receptor saturation rather than systemic hormonal signalling.

The subsequent Phase IIb OPTIONS trial enrolled 536 subjects over 24 weeks. The primary endpoint, statistically significant weight loss versus placebo, was not met. Commercial development was terminated in 2007. Rodgers 2012 The FDA's 2023 briefing to the Pharmacy Compounding Advisory Committee cited the lack of sufficient clinical evidence for therapeutic compounding approval. FDA PCAC 2023

What this means practically for research dosage decisions:

• Doses above 1 mg/day are not supported by efficacy data and appear to produce diminishing returns.
• The 250–500 mcg subcutaneous range used in current research contexts sits below the 1 mg clinical trial dose, partly because subcutaneous bioavailability differs from the oral administration used in some trial arms.
• Six trials involving approximately 900 participants confirmed no treatment-related serious adverse events, no IGF-1 elevation, no cardiovascular events, and no immunogenic response. Walker 2020

AOD-9604 Dosage Protocol: Subcutaneous Injection Timing

For subcutaneous research use, 250–500 mcg once daily is the standard starting range. Morning administration in a fasted state is the most commonly cited timing because endogenous fat mobilisation is naturally elevated after an overnight fast, theoretically amplifying the lipolytic signal from the peptide.

The fasted morning window matters for two reasons. First, insulin is at its nadir after an overnight fast, and elevated insulin suppresses lipolysis via the PI3K pathway. Injecting AOD-9604 into a low-insulin environment removes a competing brake on fat mobilisation. Second, catecholamine levels and sympathetic nervous system activity are relatively elevated in the early morning, providing a favourable hormonal backdrop for beta-3 adrenergic activation. (Note: this timing rationale is practitioner-derived and anecdotal; no RCT has directly compared fasted morning versus other timing windows for subcutaneous AOD-9604.)

Practical injection protocol:

• Dose: 250 mcg to start; titrate to 500 mcg if well tolerated after 2 weeks.
• Timing: Upon waking, 30–60 minutes before food or exercise. Anecdotal evidence suggests AM injection before fasted cardio may amplify the lipolytic window.
• Site: Subcutaneous injection into abdominal adipose tissue. Rotate injection sites at least 1 inch apart with each injection to prevent lipohypertrophy.
• Split dosing: Some practitioners split the daily dose into 250 mcg AM and 250 mcg pre-sleep on the rationale that two smaller pulses maintain steadier receptor exposure. This is anecdotal and not clinically validated.
• Reconstitution: Standard bacteriostatic water reconstitution applies. Refrigerate post-reconstitution. Discard after 28 days.

Always work with a qualified clinician before making changes to your health protocol.

Fasted Cardio Stacking: The Logic and the Limits

Stacking AOD-9604 with fasted cardio exploits the same low-insulin, elevated-catecholamine state that makes morning timing attractive. The hypothesis is that AOD-9604's lipolytic activation releases free fatty acids into circulation, and fasted moderate-intensity cardio burns those mobilised fatty acids before insulin-driven re-esterification occurs. The evidence for this synergy is mechanistic and anecdotal, not from controlled human trials.

The fasted cardio stack protocol most commonly described in research communities:

1. Wake up fasted (8–12 hours post last meal).
2. Inject AOD-9604 (250–500 mcg subcutaneous).
3. Wait 20–30 minutes.
4. Perform 30–45 minutes of moderate-intensity cardio (60–70% maximum heart rate). Low-intensity aerobic work at this intensity preferentially burns fatty acids over glucose, which theoretically aligns with the liberated free fatty acids from AOD-9604 stimulation.
5. Break the fast with a high-protein meal after cardio.

Intensity matters. High-intensity interval training in the fasted state shifts fuel utilisation toward glucose and may not capitalise on the lipolytic window. Zone 2 aerobic work is the mechanistically coherent choice here.

Stacking with other peptides targeting different mechanisms (such as GH secretagogues that work through the GHRH axis rather than direct fat-cell signalling) is theoretically additive. However, optimal multi-compound stacking protocols for AOD-9604 remain unvalidated in human trials. Cooke 2011

Cycling AOD-9604: Duration, Breaks, and Receptor Sensitivity

Typical AOD-9604 research protocols run 12–24 weeks, mirroring the clinical trial durations that generated the primary efficacy data. Cycling breaks after this window are recommended on the hypothesis that extended beta-3 adrenergic receptor stimulation leads to receptor downregulation and reduced lipolytic response over time.

The receptor sensitivity rationale for cycling is mechanistic rather than directly evidenced. Beta-3 adrenergic receptors can desensitise under chronic agonist exposure, a phenomenon documented in the context of other beta-adrenergic agonists. Whether AOD-9604 at research doses causes clinically meaningful receptor downregulation in humans is unknown. The recommendation for breaks is therefore precautionary and anecdotal rather than evidence-based. (Labelled anecdotal.)

Working cycling frameworks cited in research communities:

• 12-week on / 4-week off: Aligned with the shorter Phase II trial duration. Suitable for more aggressive fat-loss phases.
• 16-week on / 4-week off: Extends into the range of the Phase IIb trial duration while building in a recovery window.
• 24-week continuous: Mirrors the longest human trial duration. Phase IIb ran to 24 weeks without reported safety signals. Rodgers 2012

Long-term safety data beyond 24 weeks in humans is absent from the published literature. This is a meaningful evidence gap.

Maintenance phase: Some practitioners drop to 250 mcg every other day during maintenance phases to sustain modest lipolytic tone without driving full receptor engagement daily. This is anecdotal and practitioner-derived, not clinically validated.

Safety Profile: What Clinical Trials Actually Documented

Across six clinical trials involving approximately 900 participants, AOD-9604 produced no treatment-related serious adverse events, no immunogenic response, no IGF-1 elevation, and no adverse cardiovascular or metabolic signals. Its safety profile was statistically indistinguishable from placebo on all measured parameters.

This is the compound's most clinically robust finding. While the efficacy data did not survive the Phase IIb primary endpoint, the safety dataset across 900 participants is unusual for a research peptide and is consistently cited as the basis for continued investigational interest. Walker 2020

Key safety distinctions from full-length hGH:

• No IGF-1 elevation (confirmed across trials). This separates it from the oncogenic risk concerns associated with supraphysiological IGF-1.
• No glucose metabolism disruption. Preclinical euglycaemic clamp data showed no impairment of insulin sensitivity at therapeutic doses. Heffernan 2001a
• No hyperglycaemia observed in animal models even at doses producing significant fat oxidation. Heffernan 2001b
• No antibody formation or immunogenic response detected across trials.

What is not documented: long-term safety beyond 24 weeks in humans. The clinical programme ended in 2007. Researchers using AOD-9604 beyond that window are operating in an evidence gap.

Beyond Fat Loss: Cartilage and Joint Health Data

A 2015 rabbit osteoarthritis model found that intra-articular injection of AOD-9604 at 0.25 mg weekly over 4–7 weeks enhanced cartilage regeneration, with greater effect when combined with hyaluronic acid. This is preclinical data only, but it signals potential applications beyond fat metabolism that researchers have begun exploring.

The cartilage finding is notable because it suggests the peptide acts through pathways relevant to connective tissue repair, not only lipolysis. The combination with hyaluronic acid (6 mg) in the rabbit model produced superior outcomes to either compound alone, which has led some practitioners to explore AOD-9604 in joint health contexts. Gunel 2015

This is early preclinical data from one animal model. No human trials on AOD-9604 for joint health have been published. This remains an area of investigational interest rather than documented clinical application.

Regulatory Status and Research Context

AOD-9604 is not FDA-approved for any therapeutic indication. Commercial development was discontinued in 2007 after the Phase IIb trial failed to meet its primary endpoint. It is currently available for research purposes only. The FDA's 2023 PCAC briefing document cited insufficient clinical evidence to support therapeutic compounding approval.

The regulatory position is unambiguous. The compound exists in a research context, not a therapeutic one. Practitioners who work with AOD-9604 do so under research-use frameworks, and the evidence base for efficacy, while mechanistically interesting, did not survive the Phase IIb primary endpoint test. FDA PCAC 2023

For sourcing guidance and vendor evaluation criteria, see our recommended sources page. Third-party certificate of analysis (CoA) verification from an accredited analytical laboratory is the minimum standard for any research compound purchase.

Related Reading on the Underground Biohacking Blog

For a comparative look at growth hormone-adjacent peptides used in body composition research, the tesamorelin versus ipamorelin breakdown covers two GHRH-axis secretagogues that operate through a completely different mechanism from AOD-9604 and are often considered in parallel research contexts.

References

1. Rodgers RJ et al. (2012). Obesity Pharmacotherapy: Current Perspectives and Future Directions. Current Pharmaceutical Design.
2. Cooke DW, Divall SA, Radovick S. (2011). Central and Peripheral Molecular Targets for Anti-Obesity Pharmacotherapy. Endocrine Reviews.
3. Heffernan MA et al. (2001). Metabolic Studies of a Synthetic Lipolytic Domain (AOD9604) of Human Growth Hormone. Journal of Peptide Research.
4. Heffernan MA et al. (2001). Increase of Fat Oxidation and Weight Loss in Obese Mice Caused by Chronic Treatment with Human Growth Hormone or a Modified C-terminal Fragment. Journal of Endocrinology.
5. FDA. (2023). Briefing Document: Pharmacy Compounding Advisory Committee (PCAC) Meeting.
6. Gunel G et al. (2015). Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Acta Orthopaedica et Traumatologica Turcica.
7. Ng FM. (2002). Treatment of Obesity. U.S. Patent 6,335,319.
8. Walker J et al. (2020). Use of Growth Hormone Fragments. U.S. Patent 10,758,593.

This content is for educational purposes only. These compounds are intended for research use. Nothing here is medical advice. Always work with a qualified clinician before making changes to your health protocol.